Volume 2, Issue 3, September 2018, Page: 55-60
Contrast-Induced Nephropathy Among Patients Undergoing Cardiac Catheterization
Safauldeen Ahmed Alhajim, Department of Medicine, University of Basrah, Basrah, Iraq
Ahmed Sami Jebur, Department of Medicine, Shifa Hospital, Basrah, Iraq
Received: Aug. 25, 2018;       Accepted: Sep. 20, 2018;       Published: Oct. 17, 2018
DOI: 10.11648/j.ccr.20180203.12      View  240      Downloads  12
Abstract
Contrast-induced nephropathy is an important complication after cardiac catheterization, and is associated with accelerated renal disease, increased costs, mortality rate, need for dialysis and prolonged hospital stay. This study aim is to find its incidence and risk factors. It is a cross-sectional study on 160 patients admitted for diagnostic or therapeutic percutaneous coronary intervention in Basra Cardiac Center, from March to September 2016. Data collected were a complete history, examination, blood pressure, Echo study, fasting blood sugar, lipid profile, blood urea, serum creatinine and estimated glomerular filtration rate, the type and duration of procedure, volume of contrast, and after 48 hours renal function tests were repeated. Contrast-induced nephropathy has developed in 7 (8.3%) men and 5 (6.6%) women; 11 (10.8%) from 102 patients with dyslipidemia (P = 0.03); 8 (22.2%) from 36 with preexisting renal impairment (P = 0.01); 11 (10.9%) from 101 with hypertension (P = 0.02); 9 (13.6%) from 66 diabetic (P = 0.016); 9 (17.3%) from 52 smoker (P = 0.002); 4 (23.5%) from 17 alcohol drinkers (P = 0.026); 11 (11.2%) from 98 with ischemic heart disease (P = 0.02); and 9 (25.7%) from 35 with heart failure (P = <0.001). Also found in 1 (1.6%) from 64 diagnostic procedures; 11 (11.5%) from 96 therapeutic procedures (P = 0.016); 5 (3.7%) from 135 patients received < 300 ml of contrast; and 7 (28%) from 25 received ≥ 300 ml (P = 0.001). In conclusion contrast-induced nephropathy is aggravated by increasing age, diabetes mellitus, heart failure, ischemic heart disease, renal impairment, hypertension, dyslipidemia, smoking and alcohol use. The type of procedure (therapeutic vs. diagnostic), and large volume of contrast agent are important risk factors. Gender had no significant effect.
Keywords
Cardiac Catheterization, Contrast Media, Acute Kidney Injury
To cite this article
Safauldeen Ahmed Alhajim, Ahmed Sami Jebur, Contrast-Induced Nephropathy Among Patients Undergoing Cardiac Catheterization, Cardiology and Cardiovascular Research. Vol. 2, No. 3, 2018, pp. 55-60. doi: 10.11648/j.ccr.20180203.12
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Mehran R, Nikolsky E. International Society of Nephrology. Kidney International (2006) 69, S11–S15. doi:10.1038/sj.ki.5000368.
[2]
Parfrey P. “The clinical epidemiology of contrast-induced nephropathy,” Cardio- Vascular and Interventional Radiology, vol. 28, supplement 2, pp. S3–11, 2005.
[3]
McCullough PA. Contrast induced acute kidney injury. J Am Coll Cardiol. 2008; 51(15):1419-28.
[4]
Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taylor DA, Teo KK. Forced euvolemic dieresis with mannitol and furesomide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009; 54(4): 602-609.
[5]
Rihal CS, Textor SC, Grill DE, Berger M, Ting H, Best P et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-64.
[6]
Heyman S. N, Reichman J, and Brezis M.“Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia,” Investigative Radiology, vol. 34, no. 11, pp. 685–91, 1999.
[7]
Dickenmann M, Oettl T, and Mihatsch M. J. “Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes,” American Journal of Kidney Diseases, vol. 51, no. 3, pp. 491–503, 2008.
[8]
Pérez-Topete SE, Miranda-Aquino K, Gasca-Luna, MN, and Elizondo-Adamchik HE. Contrast- Induced nephropathy in patients undergoing percutaneous coronary intervention. Revista Mexicana de Cardiología. Vol. 27 No. 2.64-70, 2016.
[9]
Wichmman JL, Katzberg RW, Litwin SE, Zwerner P, Cecco CN, Vogl TJ et al. Contrast-Induced Nephropathy. Circulation. 2015; 132: 1931-36.
[10]
Kane G. C, Doyle B. J, Lerman A, Barsness G. W, Best P. J, and Rihal C. S. “Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography,” Journal of the American College of Cardiology, vol. 51, no. 1, pp. 89–90, 2008.
[11]
ACR committee on drugs and contrast media. ACR manual on Contrast media, Version 10. 1. American college of radiology. Published 2015 Accessed December 26, 2016.
[12]
Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet. 2014; 383(9931):1814-23.
[13]
Zoungas S, Ninomiya T, Huxley R, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med. 2009; 151(9):631-38.
[14]
ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124(11):1250-59.
[15]
Patti G, Nusca A, Chello M, et al., “Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention,” American Journal of Cardiology, vol. 101, no. 3, pp. 279–85, 2008.
[16]
Cruz DN, Goh CY, Marenzi G, et al. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systemic review. Am J Med. 2012 Jan; 125(1):66-78.
[17]
Marenzi G, Lauri G, Campodonico J, et al. “Comparison of two hemofiltration protocols for prevention of contrast induced nephropathy in high-risk patients,” American Journal of Medicine, vol. 119, no. 2, pp. 155–62, 2006.
[18]
Levey AS and Stevens LA. Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and Better Risk Predictions. Am J Kidney Dis. 2010 April; 55(4): 622–7.
[19]
Catapano A, Graham I, Backer G, Wiklund O, John Chapman M, Drexel H, et al: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal doi:10.1093 /eurheartj/ehw272.2016.
[20]
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5; 311(5):507-20.
[21]
Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 64:1929–49.
[22]
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney International Supplement, Vol 3, ISSUE 1, January (1) 2013.
[23]
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010 Jan; 33(1): S62- S69.
[24]
US Centers for Disease Control and Prevention (2010). Health behaviors of adults: United States, 2005-2007. Vital and Health Statistics, Series 10, Number 245, Appendix II, p. 80.
[25]
Dietary Guidelines for Americans 2015-2020,” U.S. Department of Health and Human Services and U.S. Department of Agriculture.
[26]
McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33:1787–1847.
[27]
Gussenhoven MJ, Ravensbergen J, van Bockel JH et al. Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease. J Cardiovasc Surg (Torino) 1991; 32: 81–86.
[28]
Chen S. L, Zhang J, Yei F, et al., “Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine,” International Journal of Cardiology, vol. 126, no. 3, pp. 407–13, 2008.
[29]
Marenzi G, Lauri G, Assanelli E, et al., “Contrast-induced nephropathy inpatients undergoing primary angioplasty for acute myocardial infarction,” Journal of the American College of Cardiology. 2004. vol. 44, no. 9, pp. 1780–85.
[30]
Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O'Neill WW: Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004.93:1515-19.
[31]
Bagshaw S. M and Culleton B. F. “Contrast-induced nephropathy: epidemiology and prevention,” Minerva Cardioangiologica. 2006. vol. 54, no. 1, pp. 109–29.
[32]
Liu YH, Liu Y, Chen JY, et al. LDL cholesterol as a novel risk factor for contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Atherosclerosis 2014; 237:453–9.
[33]
Na KY, Kim CW, Song YR, Chin HJ, and Chae DW. ''The Association between Kidney Function, Coronary Artery Disease and Clinical Outcome in Patients Undergoing Coronary Angiography,'' J Korean Med Sci. 2009 Jan; 24(Suppl 1): S87–S94.
[34]
Dangas G, Iakovou I, Nikolsky E, et al., “Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables,” American Journal of Cardiology. 2005. vol. 95, no. 1, pp. 13–19.
[35]
McCullough P. A, Adam A, Becker C. R, et al., “Risk prediction of contrast-induced nephropathy,” American Journal of Cardiology. 2006. vol. 98, no. 6, pp. 27–36.
[36]
Orth SR: Smoking–a renal risk factor. Nephron. 2000, 86: 12-26.
[37]
Marchi S. D, Cecchin E, Basile A, Bertotti A, Nardini R, and Bartoli E."Renal Tubular Dysfunction in Chronic Alcohol Abuse- Effects of Abstinence" N Engl J Med. Dec 1993; 329:1927-34.
[38]
Khan MZ, Faruqi R. Contrast-Induced Nephropathy. J Med Sci 2018; 26: (1) 79-84.
[39]
Assareh A, Yazdankhah S, Majidi S, Nasehi N, Beladi Mousavi SS. Contrast induced nephropathy among patients with normal renal function undergoing coronary angiography. J Renal Inj Prev. 2016; 5(1):21-24. DOI: 10.15171/jrip.2016.05.
[40]
Xiaole Su, Xingfang Xie, Lijun Liu, Jicheng Lv, Fujian Song, Vlado Perkovic, Hong Zhang. Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis. American Journal of Kidney Diseases. Volume 69, Issue 1, January 2017, Pages 69-77.
Browse journals by subject